OSTEOSARCOMA

TRIAL 1- We are now enrolling dogs with osteosarcoma who have undergone amputation and chemotherapy in a study of the Canine Osteosarcoma Vaccine, Live Listeria Vector (COV-LLV), a conditionally licensed product. 

Craig A Clifford DVM, MS, DACVIM (Oncology)
Primary Investigator

Kate Vickery, VMD, MS, DACVIM, CVA; Christine Mullin, VMD, Diplomate ACVIM (Oncology); Kristen Kicenuik, DVM, DACVIM (Oncology)
Co-Investigators

————

Study Description

————

For more information, please contact us:

P: (610) 296-2099

E: [email protected]


TRIAL 2- Evaluation of progression-free survival and immunological response to a vaccine administered to dogs receiving definitive surgery and adjuvant carboplatin chemotherapy for spontaneous appendicular osteosarcoma.

Craig A Clifford DVM, MS, DACVIM (Oncology)
Primary Investigator

Kate Vickery, VMD, MS, DACVIM, CVA; Christine Mullin, VMD, Diplomate ACVIM (Oncology); Kristen Kicenuik, DVM, DACVIM (Oncology)
Co-Investigators

————

Study Description

Osteosarcoma is the most common primary bone tumor in dogs. Surgery (usually amputation) followed by carboplatin chemotherapy is the considered the standard of care treatment, with the median survival time approaching 1 year.  The objectives of this study are to evaluate the safety and efficacy of a novel immunomodulator in dogs as an adjunct treatment for osteosarcoma.   

Inclusion Criteria

  •      Dogs must be at least 2 years of age.
  •      Dogs must weigh >25 kg with histologically confirmed, HER2 positive osteosarcoma of the appendicular skeleton.
  •    Dogs must have measurable disease amenable to limb amputation with no evidence of distant metastasis (tumor spread). 
  •   Dogs may not have received long-acting steroids within 30 days prior to enrollment, or other forms of immunotherapy previously
  •   Dogs with any serious underlying diseases (tumor metastases, heart disease, renal disease, liver disease, autoimmune disease, chronic infectious diseases and/or other cancers) are not eligible to participate
  •      Dogs must reside with their owners within driving distance of Hope VS.
  •     Owners must sign a consent form including consent for necropsy if an unexpected death occurs during the study.

Exclusion Criteria

Dogs that have received previous treatment for osteosarcoma are not eligible for this trial.
_____

Dogs will undergo preliminary staging tests including initial consultation, physical examination, lab work, thoracic radiographs, and tumor biopsy to determine trial eligibility.   All eligible dogs will undergo amputation of the affected limb followed by carboplatin chemotherapy every 3 weeks for up to 4 doses.  ALL dogs will receive immunotherapy in conjunction with carboplatin therapy. The initial immunotherapy treatment series or placebo (4 injections) will be administered every 2 weeks.  Boosters will occur one month following completion of the initial series and then every 3 months thereafter until removal from the study. Preliminary staging tests, amputation, carboplatin treatments, immunotherapy treatments and follow-up visits after completion must be performed at Hope VS.  Dogs will remain in the study until osteosarcoma metastasis is documented.

Funding

This study is partially funded by the Sponsor to help offset the costs of carboplatin and immunotherapy treatments (including administration costs), in addition, to recheck exams, repeat labwork (up to 4 CBCs, 2 biochemistry profiles, 2 urinalyses) and chest x-rays for restaging.  Owners are responsible for the costs initial consult visit, tests required for enrollment eligibility screening, amputation surgery, lab work and chest x-rays in excess of those covered by the study, and treatment of any adverse events. The funding for the trials is given at various milestone time points.

Duration of Study

The study is currently OPEN. Enrollment opportunities are limited and will terminate when the target enrollment is filled.

Potential benefits to veterinary medicine

We expect standard of care treatment in addition to immunotherapy will significantly improve disease-free interval and overall survival time in dogs with osteosarcoma over the standard of care treatment alone.
————

For more information, please contact us:

P: (610) 296-2099

E: [email protected]